← Back to Screener
AstraZeneca PLC (AZN)
Price$200.47
Favorite Metrics
Price vs S&P 500 (26W)10.13%
Price vs S&P 500 (4W)-3.29%
Market Capitalization$229.00B
P/E Ratio (Annual)30.31x
Indicated Dividend Yield (Annual)1.59%
All Metrics
P/CF (Annual)21.26x
Book Value / Share (Quarterly)$31.38
P/TBV (Annual)26.66x
Indicated Dividend (Annual)$244.70
Revenue Growth (3Y)9.82%
Cash Flow / Share (Quarterly)$5.59
Payout Ratio (TTM)48.62%
Price vs S&P 500 (YTD)5.20%
Gross Margin (TTM)81.31%
Net Profit Margin (TTM)17.41%
EPS (TTM)$6.55
10-Day Avg Trading Volume1.37M
EPS Excl Extra (TTM)$6.55
Revenue Growth (5Y)17.15%
EPS (Annual)$6.55
Dividend / Share (Annual)$3.21
ROI (Annual)13.06%
Gross Margin (Annual)81.31%
Net Profit Margin (5Y Avg)10.23%
Cash / Share (Quarterly)$3.70
P/E Basic Excl Extra (TTM)30.31x
Revenue Growth QoQ (YoY)4.11%
EPS Growth (5Y)21.88%
P/E Normalized (Annual)30.31x
ROA (Last FY)8.96%
Revenue Growth TTM (YoY)8.63%
EBITD / Share (TTM)$11.40
ROE (5Y Avg)12.53%
Operating Margin (TTM)23.40%
Cash Flow / Share (Annual)$5.59
P/B Ratio6.37x
P/B Ratio (Quarterly)5.93x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.68x
Net Interest Coverage (TTM)10.25x
ROA (TTM)9.15%
EPS Growth QoQ (YoY)55.36%
EV / EBITDA (TTM)18.75x
EPS Incl Extra (Annual)$6.55
Current Ratio (Annual)0.94x
Quick Ratio (Quarterly)0.72x
3-Month Avg Trading Volume1.31M
52-Week Price Return44.00%
EV / Free Cash Flow (Annual)38.50x
P/E Incl Extra (TTM)30.31x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$6.98
P/S Ratio (Annual)5.28x
Asset Turnover (Annual)0.51x
52-Week High$15730.00
Operating Margin (5Y Avg)14.21%
EPS Excl Extra (Annual)$6.55
CapEx CAGR (5Y)17.77%
Tangible BV CAGR (5Y)-2.48%
26-Week Price Return14.11%
Quick Ratio (Annual)0.72x
13-Week Price Return5.41%
Total Debt / Equity (Annual)0.61x
Current Ratio (Quarterly)0.94x
Enterprise Value$333,783.869
Revenue / Share Growth (5Y)13.15%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)21.40%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.85x
Pretax Margin (Annual)21.11%
Cash / Share (Annual)$3.70
3-Month Return Std Dev26.05%
Gross Margin (5Y Avg)80.17%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)22.21%
EBITDA Interim CAGR (5Y)13.17%
ROE (Last FY)21.01%
Net Interest Coverage (Annual)10.25x
EPS Basic Excl Extra (Annual)$6.55
P/FCF (TTM)35.74x
Receivables Turnover (TTM)4.17x
EV / Free Cash Flow (TTM)38.50x
Total Debt / Equity (Quarterly)0.61x
EPS Incl Extra (TTM)$6.55
Receivables Turnover (Annual)4.74x
ROI (TTM)13.32%
Dividend Growth Rate (5Y)3.33%
P/S Ratio (TTM)5.28x
Pretax Margin (5Y Avg)11.43%
Revenue / Share (Annual)$37.60
Tangible BV / Share (Annual)$6.98
Forward P/E19.60x
Free OCF CAGR (5Y)31.64%
Price vs S&P 500 (52W)14.17%
P/E Ratio (TTM)30.31x
EPS Growth TTM (YoY)45.41%
Year-to-Date Return7.08%
5-Day Price Return-3.34%
EPS Normalized (Annual)$6.55
ROA (5Y Avg)5.03%
Net Profit Margin (Annual)17.41%
Month-to-Date Return0.52%
Cash Flow / Share (TTM)$5.82
EBITD / Share (Annual)$11.40
EPS Growth (3Y)45.90%
Operating Margin (Annual)23.40%
LT Debt / Equity (Annual)0.51x
P/CF (TTM)21.26x
ROI (5Y Avg)7.37%
P/E Excl Extra (TTM)30.31x
LT Debt / Equity (Quarterly)0.51x
EPS Basic Excl Extra (TTM)$6.55
P/TBV (Quarterly)26.66x
Payout Ratio (Annual)48.62%
P/B Ratio (Annual)5.93x
Dividend / Share (TTM)$3.21
Inventory Turnover (TTM)1.85x
Pretax Margin (TTM)21.11%
Book Value / Share (Annual)$31.38
Price vs S&P 500 (13W)4.72%
Net Margin Growth (5Y)7.71%
Dividend Yield (TTM)1.60%
Beta1.06x
P/FCF (Annual)35.74x
Revenue / Share (TTM)$37.58
ROE (TTM)22.68%
52-Week Low$9651.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.12
4.15
4.15
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 2.61x | 4.11% | 72.67% | -0.54% | $57.13 |
About
AstraZeneca is a multinational pharmaceutical company formed in 1999 through the merger of Sweden's Astra and UK-based Zeneca. The company develops and markets branded drugs across oncology (over 40% of revenue), cardiovascular and metabolic diseases (20%+), rare diseases, and respiratory and immunology. Its revenue is geographically diversified, with approximately one-third of sales derived from the United States and the remainder from international markets.